Table 2. Surgical Findings and Interventions.

Characteristic	Patients, No. (%) (N = 99)
Time from presentation to surgery, mean (SEM), y	0.2 (0.1)
Preoperative treatment
Peptide receptor radionuclide therapy	1 (1.0)
Chemotherapy	3 (3.0)
Primary tumor size, mean (SEM), cm	4 (0.3)
Tumor grade
1	54 (54.6)
2	30 (30.3)
3	1 (1.0)
Not available	14 (14.1)
Invasion into surrounding structures
Stomach	4 (4.0)
Bowel	2 (2.0)
Kidney	2 (2.0)
Adrenal	1 (1.0)
Other	1 (1.0)
Lymph node involvement	37 (37.4)
Positive lymph nodes, mean (SEM), No.	3.0 (3.0)
Pancreatic surgical treatment
Pancreatectomy
Distal	43 (43.4)
Subtotal	25 (25.3)
Total	10 (10.1)
Whipple resection	18 (18.2)
Enucleation	2 (2.0)
Other	1 (1.0)
Vascular reconstruction	17 (17.2)
Portal vein	9 (9.1)
Superior mesenteric
Vein	15 (15.2)
Artery	2 (2.0)
Celiac resection	2 (2.0)
Additional resections
Cholecystectomy	21 (21.2)
Splenectomy	71 (71.7)
Kidney resection	2 (2.0)
Adrenalectomy	1 (1.0)
Bowel resection	2 (2.0)
Gastric resection	4 (4.0)
Positive margins on pathology	16 (16.0)
30-d postoperative mortality	2 (2.0)
Postoperative treatment for advanced disease	16 (16.0)
Somatostatin analogue	13 (13.1)
Chemotherapy	4 (4.0)
Biologics	3 (3.0)
Peptide receptor radionuclide therapy	2 (2.0)
ECOG at last follow up
0	47 (47.5)
1	28 (28.2)
2	8 (8.0)
3	1 (1.0)
4	0 (0.0)
5	8 (8.0)
Unknown	7 (7.0)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.